Wilson, A, Hickie, I, Lloyd, A et al. · International journal of immunopharmacology · 1995 · DOI
Researchers followed 103 ME/CFS patients for an average of 3.2 years to see if their immune system function predicted how well they would recover. Most patients improved over time, but about one-third remained unable to work. The study found that immune cell measurements taken at the start did not seem to predict who would get better or worse.
Understanding what drives long-term outcomes in ME/CFS is crucial for prognostication and treatment planning. This study challenges the hypothesis that cell-mediated immune dysfunction is a key driver of disease progression or recovery, potentially redirecting research focus toward other biological mechanisms or clinical factors that better predict prognosis.
This study does not prove that immune dysfunction plays no role in ME/CFS pathophysiology—only that standard cell-mediated immune measurements at baseline did not predict individual outcomes. It does not establish which factors (if any) do predict recovery or persistent disability. Absence of correlation does not rule out that immune abnormalities contribute to symptom generation in other ways.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →